Aim:
This study aims to gain insight in the effectiveness of, adherence and adjustments to guideline-based antimycobacterial therapy in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the first 6 months of treatment.

Summary:
Mycobacterium avium complex pulmonary disease (MAC-PD) is an emerging health problem with  unsatisfactory treatment outcomes. The frequent occurrence of drug toxicity and low adherence to guideline-based treatment (GBT) are key reasons for the limited treatment success. Hence, there is an unmet need for prospective data on effectiveness of, adherence and adjustments to MAC-PD treatment. This collaboration between NTM-NET and ESGMYC affiliated medical centers enables systematic and prospective data collection of an international MAC-PD cohort (for more information, see clinicaltrial.gov ID: NCT05906316).